The HPA Health Group performed a corneal crosslinking treatment for the first time in the Algarve, marking an important milestone for the HPA Institute‘s Ophthalmology department and for eye healthcare in the region.
The procedure was performed by Dr. Pedro M. Baptista, whose dedication enabled the introduction of this innovative technique at HPA Health Group.
Crosslinking is a treatment indicated to stabilize the progression of degenerative corneal diseases, which primarily affect young patients and, in the most severe cases, can progress to severe complications, including significant vision loss.
The implementation of this treatment in the Algarve represents a significant advance in terms of proximity, accessibility, and continuity of specialized ophthalmological care.
This step reinforces the HPA Institute’s commitment to providing differentiated and technologically advanced clinical solutions, aligned with national and international best practices. The HPA Institute’s Ophthalmology service maintains a multidisciplinary approach, allowing it to respond more effectively and personalized to patients’ needs. It currently constitutes the most distinguished centre in the Algarve for ophthalmic diagnosis and surgery.
With the completion of the first Crosslinking treatment in the Algarve, the HPA Health Group consolidates its position as a leading provider of differentiated healthcare in the south of the country, reiterating its commitment to clinical innovation, proximity, and excellence in meeting the needs of the population.
Sponsored Content
